Please login to the form below

Not currently logged in
Email:
Password:

Vertex Pharma

This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.

Vertex gains FDA fast track designation for diabetes stem cell therapy

Vertex gains FDA fast track designation for diabetes stem cell therapy

Vertex gained VX-880 from its previous acquisition of Semma Therapeutics for $950m in September 2019. ... This will help to protect the islet cells from immune rejection, Vertex said in a statement.

Latest news

More from news
Approximately 6 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Health trust in a COVID-19 world – a unique opportunity for pharma Health trust in a COVID-19 world – a unique opportunity for pharma

    There were also some high-profile reimbursement stand-offs between pharma and the NHS (eg, Vertex/Orkambi). ... to the pharma industry, which is seen as being responsible for the high price of medicines).

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast ... Meticulous preparations. The

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.

  • The Orkambi blame game The Orkambi blame game

    The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out in a parliamentary hearing in London on 7 March, when the company’s CEO ... NHS England accusing Vertex of being an“extreme outlier” and

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Vertex poaches new finance chief from Ironwood Pharmaceuticals Vertex poaches new finance chief from Ironwood Pharmaceuticals

    Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,

  • BMS appoints three independent directors BMS appoints three independent directors

    Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics